HuR Regulates GATA3-Driven Type 2 Inflammation in CD4⁺ T cells and ILC2 in Airway Inflammation

Type 2-high asthma is driven by coordinated GATA3-dependent programs in CD4⁺ T cells and group 2 innate lymphoid cells (ILC2). Although biologics targeting Th2 cytokines benefit subsets of patients, many remain symptomatic, suggesting upstream regulatory mechanisms may sustain type 2 inflammation. We investigated whether the RNA-binding protein HuR (ELAVL1) functions as a post-transcriptional regulator of GATA3-driven type 2 inflammation in allergic asthma. Using a house dust mite (HDM) model in vivo, HuR inhibition with KH-3 reduced lung inflammation, suppressed Th2 cytokine expression, accelerated Gata3 mRNA decay in lung CD4⁺ T cells, and attenuated airway hyperresponsiveness toward control levels. In ex vivo-activated human lung CD4⁺ T cells, KH-3 accelerated GATA3 mRNA decay with minimal effects on RORC or TBX21 and selectively reduced Th2 cytokine secretion, while IL-10 and IL-2 were unchanged. Similarly, ILC2s isolated from PBMCs of type 2-high asthmatic donors showed reduced GATA3 mRNA stability and diminished Th2 cytokine production following KH-3 treatment. Single-cell transcriptomic analysis of bronchoalveolar lavage fluid after allergen challenge in asthmatic subjects demonstrated co-enrichment of ELAVL1 and GATA3 within Th2 clusters in human airways. Together, these findings identify HuR as a therapeutically targetable upstream regulator of GATA3-driven type 2 inflammation in allergic asthma.